Abiraterone

證據等級: L5

預測適應症: 0 個

Abiraterone: Evaluation Incomplete — TxGNN Predictions Pending

One-Sentence Summary

Abiraterone (DB05812) is a well-established CYP17A1 inhibitor used for metastatic castration-resistant prostate cancer, approved by the US FDA under the brand name Zytiga. However, no TxGNN repurposing predictions were generated in this Evidence Pack, and the Taiwan TFDA query returned zero results. This report reflects a data-limited evaluation and serves primarily as a gap analysis and triage document.

Quick Overview

Item	Content
Original Indication	Not captured in this Evidence Pack (known: prostate cancer from US FDA approval)
Predicted New Indication	None — TxGNN predictions not available
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction not yet generated; no supporting studies via this pipeline)
Taiwan Market Status	✗ Not marketed (TFDA query returned 0 results)
Number of Taiwan Licenses	0
Recommended Decision	Hold

Why No Prediction Was Generated

The predicted_indications array in this Evidence Pack is empty, indicating one of the following conditions:

Pipeline incomplete: The KG and DL prediction steps did not complete for this drug in the current run.
Mapping failure: Abiraterone (DB05812) may not have been successfully matched to the TxGNN knowledge graph node, preventing score generation.
Filtered out: Scores fell below the minimum threshold and were excluded from output.

Without a predicted indication, the core analysis sections (mechanism applicability, clinical trial evidence, literature evidence) cannot be meaningfully constructed from this Evidence Pack alone.

⚠️ Note: From public pharmaceutical knowledge, Abiraterone acetate (Zytiga) is a US FDA-approved CYP17A1 inhibitor for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC). It is broadly marketed internationally. The Taiwan TFDA returning 0 results is likely a query issue (possible brand/salt name mismatch) rather than true absence from the Taiwan market.

Taiwan Market Information

No Taiwan TFDA licenses were retrieved. This is likely a data quality issue:

Query Source	Query Date	Status	Records Found
TFDA	2026-03-24	Success	0

Suggested remediation: Re-query TFDA using the brand name “Zytiga” or the acetate salt form “Abiraterone Acetate” (醋酸阿比特龍) to capture any registered licenses.

Cytotoxicity

Abiraterone is classified as an antineoplastic agent (prostate cancer) and warrants a cytotoxicity entry, though it is not a conventional cytotoxic drug.

Item	Content
Cytotoxicity Classification	Targeted hormonal therapy (CYP17A1 androgen biosynthesis inhibitor) — not a conventional cytotoxic
Myelosuppression Risk	Low (not myelosuppressive; not a chemotherapy agent)
Emetogenicity Classification	Low
Monitoring Items	Liver function (ALT/AST), blood pressure, serum potassium, fluid retention; adrenocortical function if used without prednisone
Handling Protection	Standard oral hazardous drug precautions apply (NIOSH list); no cytotoxic IV handling requirements

Safety Considerations

All safety fields in this Evidence Pack are marked as data gaps. No DDI records were found.

Please refer to the US FDA-approved package insert for Zytiga (abiraterone acetate) for complete warnings, contraindications, and drug interaction information. Key known safety concerns include hepatotoxicity, hypertension, hypokalemia, and adrenocortical insufficiency, particularly when co-administered with prednisone.

Data Gaps Requiring Resolution

Gap ID	Item	Severity	Remediation
DG001	Taiwan TFDA package insert (warnings/contraindications)	Blocking	Re-query TFDA using “Zytiga” or “醋酸阿比特龍”; download and parse PDF
DG002	Mechanism of action (MOA)	High	Query DrugBank API for DB05812
—	TxGNN predicted indications	Critical	Re-run KG + DL prediction pipeline; verify DB05812 is mapped in `drugbank_vocab.csv`
—	TFDA license records	High	Re-query with alternate drug names/salt forms

Conclusion and Next Steps

Decision: Hold

Rationale: This Evidence Pack is incomplete — no TxGNN predictions were generated and all safety data is unavailable. There is insufficient structured data to evaluate any repurposing hypothesis for Abiraterone at this time.

To proceed, the following is needed:

Verify that Abiraterone (DB05812) is correctly mapped in the TxGNN knowledge graph (drugbank_vocab.csv) and re-run the prediction pipeline
Re-query TFDA using alternate names (“Zytiga”, “醋酸阿比特龍”) to retrieve Taiwan license records and package insert safety data
Retrieve MOA from DrugBank API (DB05812) to enable mechanism applicability analysis
Once predictions are generated, re-issue this Evidence Pack as v5 for full evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.